l -Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Objective The authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of L-methylfolate augmentation in the treatment of major depressive disorder in patients who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs). Method In the first trial, 148 outpatients with SSRI-resistant major depressive disorder were enrolled in a 60-day study divided into two 30-day periods. Patients were randomly assigned, in a 2:3:3 ratio, to receive L-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days), placebo for 30 days followed by L-methylfolate (7.5 mg/day) for 30 days, or placebo for 60 days. SSRI dosages were kept constant throughout the study. In the second trial, with 75 patients, the design was identical to the first, except that the l-methylfolate dosage was 15 mg/day during both 30-day periods. Results In the first trial, no significant difference was observed in outcomes between the treatment groups. In the second trial, adjunctive L-methylfolate at 15 mg/day showed significantly greater efficacy compared with continued SSRI therapy plus placebo on both primary outcome measures (response rate and degree of change in depression symptom score) and two secondary outcome measures of symptom severity. The number needed to treat for response was approximately six in favor of adjunctive L-methylfolate at 15 mg/day. L-Methylfolate was well tolerated, with rates of adverse even…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Folate has been studied in a placebo-controlled trial an adjunctive treatment to fluoxetine, with significantly greater improvement in the folate group, a difference most pronounced in women [43].”
From Complementary and alternative medicine therapies for perinatal depression (2014) · cites this paper as [43]
In the citing paper
“94% of women who received fluoxetine with the addition of folate 500 mcg per day were treatment responders, compared to 61% of those who received fluoxetine and placebo.”
From Complementary and alternative medicine therapies for perinatal depression (2014) · cites this paper as [43]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
TRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Self-citationFava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
Self-citationEnhancement of recovery from psychiatric illness by methylfolate
Godfrey, P. S. A., Toone, B. K., Bottiglien, T., Laundy, M., Reynolds, E. H., Carney, M. W. P., Flynn, T. G., & Chanarin, I. (1990) · The Lancet · doi:10.1016/0140-6736(90)91942-4 · Cited by 389
Coppen, A., & Bailey, J. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00153-1 · Cited by 337
Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled Studies
Bauer, M., & Döpfmer, S. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00006 · Cited by 304
Research works printed but not linked: 3
- 10.3109/10401230209147396 · doi:10.3109/10401230209147396 · Paper page
- Passeri M, 1993, Aging (Milano), 5, 63
- First MB, 1995, Structured Clinical Interview for DSM-IV Axis I Disorders With Psychotic Screen (SCID-I/P w/ Psychotic Screen) Version 2.0
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review
Kennedy, D. (2016) · Nutrients · doi:10.3390/nu8020068 · Cited by 1,055
“This mechanism would accommodate the observation that folate increases endothelial vasodilation via a mechanism entirely unrelated to homocysteine [57,79] and would accommodate epidemiological observations of a relationship between reduced folate status and depression and disturbed cognitive function [56,78,80].”
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“5 mg/day was ineffective (Papakostas et al., 2012).”
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“Animal data showed that SSRIs could restore deficient endothelial NO levels [219], suggesting that anti-oxidative mechanisms may contribute to their antidepressant effects.”
InfluentialDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Self-citationThe role of methionine on metabolism, oxidative stress, and diseases
Martínez, Y., Li, X., Liu, G., Bin, P., Yan, W., Más, D., Valdivié, M., Hu, C.-A. A., Ren, W., & Yin, Y. (2017) · Amino Acids · doi:10.1007/s00726-017-2494-2 · Cited by 583
Feeding the microbiota–gut–brain axis: Diet, microbiome, and neuropsychiatry
Sandhu, K. V., Sherwin, E., Schellekens, H., Stanton, C., Dinan, T. G., & Cryan, J. F. (2017) · Translational Research · doi:10.1016/j.trsl.2016.10.002 · Cited by 491
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
“Administration of L-methylfolate (marketed as Deplin and Zervalx) to patients with MDD has been shown to augment the efficacy of standard antidepressant therapy in two studies [278, 279], however mixed results were reported in two parallel-sequential trials with only one trial finding efficacy over placebo [280].”
BackgroundMethodResultAdjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses
Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15091228 · Cited by 436
“[24] trial 1/phase 1: 7.”
Self-citationDiet, Stress and Mental Health
Bremner, J., Moazzami, K., Wittbrodt, M., Nye, J., Lima, B., Gillespie, C., Rapaport, M., Pearce, B., Shah, A., & Vaccarino, V. (2020) · Nutrients · doi:10.3390/nu12082428 · Cited by 377
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
“Papakostas et al. (2012) also evaluated the efficacy of L-methylfolate as an adjunct to SSRIs in two separate clinical trials.”
BackgroundInfluentialNajjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Self-citationThe Glutathione System: A New Drug Target in Neuroimmune Disorders
Morris, G., Anderson, G., Dean, O., Berk, M., Galecki, P., Martin-Subero, M., & Maes, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8705-x · Cited by 187
“active transport system within that structure [323, 324].”
The neurology of folic acid deficiency
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-7020-4087-0.00061-9 · Cited by 163
Almeida, O. P., Ford, A. H., & Flicker, L. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000046 · Cited by 161
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Bottiglieri, T., Roffman, J., Cassiello, C., Stahl, S. M., & Fava, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08947 · Cited by 139
“GCH1 TC/TT + MTR 2756 AG/GG 9 (15) −10.”
Self-citationThe Role of Nutrition and the Gut-Brain Axis in Psychiatry: A Review of the Literature
Mörkl, S., Wagner-Skacel, J., Lahousen, T., Lackner, S., Holasek, S. J., Bengesser, S. A., Painold, A., Holl, A. K., & Reininghaus, E. (2020) · Neuropsychobiology · doi:10.1159/000492834 · Cited by 125
Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry
Fanet, H., Capuron, L., Castanon, N., Calon, F., & Vancassel, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200729103529 · Cited by 134
“LIST OF ABBREVIATIONS A = Adrenaline Ach = Acetylcholine AADC = Aromatic L-Amino Acid Decarboxylase AD = Alzheimer Disease AGMO = Alkylglycerol Monooxygenase AAAHs = Aromatic Amino Acid Hydroxylases BBB = Blood Brain Barrier BH2 = Dihydrobiopterin BH4 = Tetrahydrobiopterin COX-2 = Cyclooxygenase-2 CSF = Cerebrospinal…”
BackgroundAiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 138
“Both L-methylfolate and SAMe have been studied in depression with limited efficacy, but the confounds in clinical trial designs described below make interpretation of the results difficult (Papakostas et al., 2010, 2012, 2014; Mischoulon et al., 2014; Sarris et al., 2018).”
BackgroundAutism and Dietary Therapy: Case Report and Review of the Literature
Herbert, M. R., & Buckley, J. A. (2013) · Journal of Child Neurology · doi:10.1177/0883073813488668 · Cited by 120
Schefft, C., Kilarski, L. L., Bschor, T., & Köhler, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.004 · Cited by 135
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Self-citationNatural products, micronutrients, and nutraceuticals for the treatment of depression: A short review
Nabavi, S. M., Daglia, M., Braidy, N., & Nabavi, S. F. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2015.1103461 · Cited by 120
Mapping inflammation onto mood: inflammatory mediators of anhedonia
Swardfager, W., Rosenblat, J. D., Benlamri, M., & McIntyre, R. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.017 · Cited by 125
Complementary and alternative medicine therapies for perinatal depression
Deligiannidis, K. M., & Freeman, M. P. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.08.007 · Cited by 124
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Mohn, E. S., Kern, H., Saltzman, E. J., Mitmesser, S. H., & McKay, D. L. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010036 · Cited by 135
“The mechanism of action underlying this relationship is not fully elucidated, although studies have shown serotonin receptors are present on osteoblasts, osteoclasts, and osteocytes, indicating SSRIs may influence bone formation and resorption through the activation of serotonin receptors [357].”
BackgroundInfluentialJacobsen, J. P. R., Krystal, A. D., Krishnan, K. R. R., & Caron, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.001 · Cited by 124
“ADK and RRK serve on the Evecxia Scientific Advisory Board. uthor M anuscript A uthor M anuscript A uthor M anuscript selective serotonin reuptake-inhibitors (SSRIs) and dual serotonin and norepinephrine reuptake inhibitors (SNRIs).”
BackgroundInfluentialCorrell, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 109
Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations
Gewandter, J. S., Dworkin, R. H., Turk, D. C., McDermott, M. P., Baron, R., Gastonguay, M. R., Gilron, I., Katz, N. P., Mehta, C. R., Raja, S. N., et al. (2014) · Pain · doi:10.1016/j.pain.2014.05.025 · Cited by 118
“In fact, all 5 publicly reported depression trials using the SPCD reported a decrease in the percentage of placebo responders between stage 1 and stage 2, although the decrease in placebo response was minimal in 1 of these trials [33,91,92] (Marshall RD, Leigh-Pemberton RA, Memisoglu A, Martin W, DeSomer M, Ehrich E,…”
BackgroundPetridou, E. T., Kousoulis, A. A., Michelakos, T., Papathoma, P., Dessypris, N., Papadopoulos, F. C., & Stefanadis, C. (2016) · Aging & Mental Health · doi:10.1080/13607863.2015.1049115 · Cited by 112
“Thus, folate and, to a lesser extent, vitamin B12 may increase the effectiveness of antidepressants in late life (Almeida et al., 2014; Alpert, Silva, & Pouget, 2003; Bell et al., 1992; Guaraldi, Fava, Mazzi, & la Greca, 1993; Papakostas et al., 2012), although evidence for the positive effects of vitamin supplementat…”
BackgroundA review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110
“…effects to augment ongoing antidepressants, producing diverse clinical results (Han et al., 2012, 2013; Iosifescu et al., 2005; Khajavi et al., 2012; Pae, 2013; Pae, in press; Pae and Forbes, 2011; Pae et al., 2008; Papakostas and Cassiello, 2012; Papakostas et al., 2006, 2012; Su and Wang, 2013).”
BackgroundFaster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“Indeed, L-methylfolate, is a medical food on the US market that has been investigated as an augmentation strategy for SSRIs and has shown some modest effects (Alpert et al., 2002; Coppen and Bailey, 2000; Papakostas et al., 2012).”
BackgroundTreatment-Resistant Depression Revisited: A Glimmer of Hope
Halaris, A. E., Sohl, E., & Whitham, E. A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020155 · Cited by 110
Firth, J., Carney, R., Stubbs, B., Teasdale, S. B., Vancampfort, D., Ward, P. B., Berk, M., & Sarris, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx162 · Cited by 91
Role of Inflammation in Depression and Treatment Implications
Felger, J. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_166 · Cited by 103
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Dissecting bipolar disorder complexity through epigenomic approach
Ludwig, B., & Dwivedi, Y. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.123 · Cited by 91
Almeida, O. P., Ford, A. H., Hirani, V., Singh, V., vanBockxmeer, F. M., McCaul, K., & Flicker, L. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.145177 · Cited by 87
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
“The efficacy of complementary/alternative medicines to treat depressive symptoms is reviewed elsewhere.66 The most compelling evidence exists for S-adenosyl methionine (SAMe) and for L-methylfolate.”
ResultInfluentialBorges-Vieira, J. G., & Cardoso, C. K. S. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2031494 · Cited by 80
“not exceed the placebo group’s reports [24,62,64,65,67] or were reported in either group [63,66].”
BackgroundLiwinski, T., & Lang, U. E. (2023) · Nutrients · doi:10.3390/nu15173859 · Cited by 89
“Research has demonstrated that individuals with folate deficiency may exhibit an inadequate response to antidepressant medications, which can contribute to the characterization of their condition as “treatmentresistant” depression [88].”
BackgroundHoepner, C. T., McIntyre, R. S., & Papakostas, G. I. (2021) · Nutrients · doi:10.3390/nu13030767 · Cited by 80
“As an adjunct, L-methylfolate has been shown to cause minimal adverse events [42,46].”
BackgroundMethodInfluentialSelf-citationPan, L. A., Martin, P., Zimmer, T., Segreti, A. M., Kassiff, S., McKain, B. W., Baca, C. A., Rengasamy, M., Hyland, K., Walano, N., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15111500 · Cited by 68
Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice.
Rosa, P. B., Ribeiro, C. M., Bettio, L., Colla, A., Lieberknecht, V., Moretti, M., & Rodrigues, A. L. S. (2014) · Pharmacology, Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.003 · Cited by 71
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 71
“Further, supplementation of folate and SAMe has been shown repeatedly in RCTs to improve MDD symptoms [115-120].”
BackgroundRoffman, J. L., Petruzzi, L. J., Tanner, A. S., Brown, H. E., Eryilmaz, H., Ho, N. F., Giegold, M., Silverstein, N. J., Bottiglieri, T., Manoach, D. S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.41 · Cited by 67
“That said, the lack of significant treatment effects on homocysteine or methionine suggests that metabolic dysfunction downstream of where methylfolate enters into the one carbon cycle – potentially due to variants that were not included in the model – may ultimately influence efficacy of Lmethylfolate in some patient…”
BackgroundMethodSelf-citationOkereke, O. I., Cook, N. R., Albert, C. M., Van Denburgh, M., Buring, J. E., & Manson, J. E. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148361 · Cited by 62
Lam, N. S. K., Long, X. X., Li, X., Saad, M., Lim, F., Doery, J. C. G., Griffin, R. C., & Galletly, C. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112541 · Cited by 62
The pro-inflammatory profile of depressed patients is (partly) related to obesity
Shelton, R. C., Falola, M., Li, L., Zajecka, J., Fava, M., & Papakostas, G. I. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.09.001 · Cited by 57
“The first set of serum samples were obtained from participants with major depressive disorder (MDD) obtained at baseline in multi-site study of the augmentation of SSRI antidepressants with l-methylfolate previously reported (n=75) (Papakostas et al., 2012).”
BackgroundInfluentialSelf-citationUse of functional imaging across clinical phases in CNS drug development
Borsook, D., Becerra, L. R., & Fava, M. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.43 · Cited by 66
Folate nutrition and blood–brain barrier dysfunction
Stover, P. J., Durga, J., & Field, M. S. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.01.006 · Cited by 63
Brennan, F. X., Gardner, K. R., Lombard, J., Perlis, R. H., Fava, M., Harris, H. W., & Scott, R. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01717 · Cited by 51
Popper, C. W. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.04.001 · Cited by 83
“It might be noted, though, that 2 of the 5 RCTs were funded by pharmaceutical manufacturers.(51,58) The available monotherapy studies of folic acid in MDD are methodologically limited.”
ResultEnergetic stress: The reciprocal relationship between energy availability and the stress response
Harrell, C. S., Gillespie, C. F., & Neigh, G. N. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.009 · Cited by 57
“L-methylfolate (Papakostas et al., 2012) is a compound administered adjunctively with conventional antidepressant therapy to remediate deficits in micronutrient status that may otherwise contribute to treatment resistance in depressed patients.”
Park, D. I., Dournes, C., Sillaber, I., Uhr, M., Asara, J. M., Gassen, N. C., Rein, T., Ising, M., Webhofer, C., Filiou, M. D., et al. (2016) · Scientific Reports · doi:10.1038/srep35317 · Cited by 51
Complementary Health Practices for Treating Perinatal Depression
Reza, N., Deligiannidis, K. M., Eustis, E. H., & Battle, C. L. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.04.002 · Cited by 45
Micronutrient intake adequacy and depression risk in the SUN cohort study
Sánchez‐Villegas, A., Perez‐Cornago, A., Zazpe, I., Santiago, S., Lahortiga‐Ramos, F., & Martínez‐González, M. Á. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1514-z · Cited by 53
“found that low dietary folate intake could be considered a risk factor for depression [38] and several clinical trials have analyzed whether the co-administration of methylfolate or folic acid with the antidepressant treatment enhanced its effect [39].”
BackgroundBDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions
Cubillos, S., Engmann, O., & Brancato, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214445 · Cited by 47
“L-Methylfolate 15 mg/d SSRIs QIDS-SR and CGI: better with L-Methylfolate in SSRI resistance [129]”
MethodLedowsky, C., Mahimbo, A., Scarf, V. L., & Steel, A. (2022) · Nutrients · doi:10.3390/nu14132715 · Cited by 47
Allott, K., McGorry, P. D., Yuen, H. P., Firth, J., Proffitt, T., Berger, G. E., Maruff, P. T., O’Regan, M. K., Papas, A., Stephens, T. C. B., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.018 · Cited by 46
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“In double-blind trials, patients treated for 60 days with L-methylfolate add-on to SSRI had greater response rate and degree of change in depression symptom score than patients receiving placebo [111]; the NNT was around 6.”
BackgroundMcCoy, C. R., Jackson, N. L., Day, J. J., & Clinton, S. M. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.008 · Cited by 43
“S-adenosyl-L-methionine (SAMe) [96-98] or Lmethylfolate [99-101]) improves depressive symptoms.”
Mitochondrial Agents for Bipolar Disorder
Pereira, C., Chavarria, V., Vian, J., Ashton, M. M., Berk, M., Marx, W., & Dean, O. M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy018 · Cited by 40
Backing into the future: pharmacological approaches to the management of resistant depression
Cowen, P. J. (2017) · Psychological Medicine · doi:10.1017/s003329171700068x · Cited by 40
“2014) L-methylfolate Methyl donor Possibly effective in a dose of 15 mg daily (Papakostas et al. 2012) Metyrapone Blocks cortisol synthesis Ineffective in a recent large trial (McAllister-Williams et al.”
BackgroundÁlvarez-Mon, M. Á., Ortega, M. A., Montero, C. G., Fraile‐Μartinez, O., Monserrat, J., Lahera, G., Mora, F., Rodríguez-Quiroga, A., Fernández-Rojo, S., Quintero, J., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080821 · Cited by 44
Nutritional strategies for dealing with depression
Manosso, L. M., Moretti, M., & Rodrigues, A. L. S. (2013) · Food & Function · doi:10.1039/c3fo60246j · Cited by 38
Shelton, R. C., Manning, J. S., Barrentine, L. W., & Tipa, E. V. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13m01520 · Cited by 38
Self-citationAdjunctive folate for major mental disorders: A systematic review
Zheng, W., Li, W., Qi, H., Xiao, L., Sim, K., Ungvari, G. S., Lu, X.-B., Huang, X., Ning, Y.-P., & Xiang, Y.-T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.096 · Cited by 37
Han, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 41
Pharmacogenetics and Psychiatric Care: A Review and Commentary
Butler, M. G. (2018) · JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY · doi:10.29245/2578-2959/2018/2.1120 · Cited by 37
Korte-Bouws, G. A. H., Albers, E., Voskamp, M. J., Hendriksen, H., de Leeuw, L. R., Güntürkün, O., de Roock, S., Vastert, S. J., & Korte, S. M. (2019) · Pharmaceuticals · doi:10.3390/ph12010009 · Cited by 40
“In agreement, there is a growing body of evidence that L-methylfolate and SAMe supplementation might improve antidepressant actions of SSRIs in patients, who normally tend not to respond well to SSRI drugs [65,91,92].”
BackgroundOne-carbon metabolism and bipolar disorder
Baek, J. H., Bernstein, E. E., & Nierenberg, A. A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413502091 · Cited by 37
“Recently, Papakostas et al. (2012) reported that adjunct 5-MTHF was effective for major depressive disorder patients who had poor response to SSRIs.”
BackgroundNeurogenesis-based epigenetic therapeutics for Alzheimer's disease (Review)
Li, X., Bao, X., & Wang, R. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5390 · Cited by 39
“For example, S-adenosylmethionine and l-methylfolate, which provide methyl groups in the body to enhance DNA methylation (4,146), have been found to improve the learning and cognitive performance associated with AD (147-149).”
Caveat emptor: Folate in unipolar depressive illness, a systematic review and meta-analysis
Roberts, E., Carter, B., & Young, A. H. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118756060 · Cited by 35
“…determined by trial psychiatrist 5 mg folate Placebo; folate therapy as an adjunct to any antidepressant at adequate dose and duration BDI-II (Papakostas et al., 2012b) (I) USA 148 DSM-IV major depressive disorder 7.5 mg for 30 days increasing to 15 mg methylfolate 30 days Group 1: placebo…”
BackgroundMethodInfluentialZajecka, J., Stanford, A. D., Memisoglu, A., Martin, W. F., & Pathak, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199245 · Cited by 34
Self-citationCurrent Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder
Childress, A. C., & Tran, C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1147558 · Cited by 33
“[61,62] L-methylfolate as a supplement to stimulant ADHD therapies was studied in an”
BackgroundSSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept
Jacobsen, J. P. R., Rudder, M. L., Roberts, W. L., Royer, E. L., Robinson, T. J., Oh, A., Spasojević, I., Sachs, B. D., & Caron, M. G. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.35 · Cited by 33
Zhang, H., Jha, A. B., Warkentin, T. D., Vandenberg, A., & Purves, R. W. (2018) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2018.04.008 · Cited by 32
Eszlári, N., Kovács, D., Petschner, P., Pap, D., Gonda, X., Elliott, R., Anderson, I. M., Deakin, J. F. W., Bagdy, G., & Juhász, G. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.19 · Cited by 31
Zajecka, J., D, M. F. M., Shelton, R. C., Barrentine, L. W., Young, P., & Papakostas, G. I. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10181 · Cited by 30
“6 (0–23) (n = 34) 34 (18) 21 (11) 6 (3) 60 (32) 26 (14) 100”
Self-citationNeuronutrients and Central Nervous System: A Systematic Review
Nogueira-de-Almeida, M. E., Filho, I. J. Z., Nogueira-de-Almeida, M. E., Souza, C. G., Kemp, V. L., & Ramos, W. S. (2022) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524923666221121123937 · Cited by 33
Varteresian, T. C., & Lavretsky, H. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0456-x · Cited by 33
McCoy, C. R., Jackson, N. L., Brewer, R. L., Moughnyeh, M., Smith, D. L., & Clinton, S. M. (2018) · Bioscience Reports · doi:10.1042/bsr20180730 · Cited by 29
When should the sequential parallel comparison design be used in clinical trials?
Baer, L., & Ivanova, A. (2013) · Clinical Investigation · doi:10.4155/cli.13.74 · Cited by 28
Self-citationNembhard, W. N., Tang, X., Hu, Z., Macleod, S. L., Stowe, Z. N., Webber, D. M., & Study, T. N. B. D. P. (2017) · BMJ · doi:10.1136/bmj.j832 · Cited by 30
Chang, F., Fan, X., Zhang, Y., Tang, B., & Jia, X. (2022) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-021-04340-0 · Cited by 27
“In addition, pregnant women who took folic acid during pregnancy had a lower risk of depressive symptoms, consistent with previous international research [50, 51].”
ResultDartois, L. L., Stutzman, D. L., & Morrow, M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0006 · Cited by 27
“This is similar to adult literature, which estimates that more than half of all adult patients treated with antidepressant monotherapy fail to reach remission (Papakostas et al. 2012).”
InfluentialA Review of Psychostimulants for Adults With Depression.
Pary, R., Scarff, J. R., Jijakli, A., TOBIAS, C. R., & Lippmann, S. (2015) · Europe PMC (PubMed Central) · Cited by 29
Giakoumatos, C. I., & Osser, D. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
How should we design future mechanistic and/or efficacy clinical trials?
D, M. F. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01600-9 · Cited by 27
“A variant of the SPCD design was mentioned in the original article by Fava et al. [8] and has been implemented in several multi-center trials, with pre-randomization to three sequences: drug-drug, placebo-drug, and placebo-placebo [42, 43].”
MethodBlampied, M., Bell, C., Gilbert, C., & Rucklidge, J. J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1740595 · Cited by 49
REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION
Rakofsky, J. J., & Dunlop, B. W. (2013) · Depression and Anxiety · doi:10.1002/da.22220 · Cited by 28
“Some nutritional supplements have demonstrated efficacy in randomized controlled trials for major depressive disorder.[15, 16] Given the need for better treatments of BD depression, we aimed to examine the evidence base for nutritional supplements through a systematic literature review.”
BackgroundWade, R. L., Kindermann, S. L., Hou, Q., & Thase, M. E. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.76 · Cited by 26
L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry
Nierenberg, A. A., Montana, R. E., Kinrys, G., Deckersbach, T., Dufour, S. C., & Baek, J. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.053 · Cited by 25
Shen, X., Yuan, H., Wang, G., Xue, H., Liu, Y., & Zhang, C.-X. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.062 · Cited by 24
Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD
Jain, R., Manning, S., & Cutler, A. J. (2019) · CNS Spectrums · doi:10.1017/s1092852919001469 · Cited by 25
“As described above, use of L-methylfolate is associated with better efficacy in patients with SSRI-resistant depression.(111) These outcomes are particularly improved in patients with the MTR 2756 AG/GG genotype, a low SAMe:SAH ratio, high BMI, or elevated levels of CRP or IL-8.”
Influential
Metadata
- Authors
- Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., Pencina, M., Meisner, A., Bottiglieri, T., Nelson, E., Mischoulon, D., Alpert, J. E., Barbee, J. G., Zisook, S., & Fava, M.
- Affiliations
- Boston University (US)
- From the Center for Treatment-Resistant Depression, Depression Clinical and Research Program, the Biostatistics Center, and the Clinical Trials Network and Institute, Massachusetts General Hospital, Boston; Harvard Medical School, Boston; the Harvard Clinical Research Institute, Boston; the Department of Biostatistics, Boston University, Boston; the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville; Rush University Medical Center, Chicago; the Department of Psychiatry,...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-12
- Volume
- 169
- Issue
- 12
- Pages
- 1267-1274
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2136722242
- Cited by
- 275
- References
- 36
- Citations by year
- 2026: 21 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 20 · 2020: 18 · 2019: 22 · 2018: 27 · 2017: 19 · 2016: 26 · 2015: 26 · 2014: 25 · 2013: 25 · 2012: 1
- FWCI
- 18.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- 5-methyltetrahydrofolate, major depressive disorder, selective serotonin reuptake inhibitors, adjunctive therapy, treatment-resistant depression, antidepressant augmentation, response rate, adverse events, folic acid supplementation
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Tetrahydrofolates, Treatment Outcome, Chemotherapy, Adjuvant, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.